By: IPP Bureau
Last updated : October 22, 2025 10:50 am
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Pfizer announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation.
"The PHAROS trial results set a new standard for NSCLC patients with the BRAF V600E mutation, with survival outcomes nearing four years—the longest survival we've seen in people with treatment-naïve metastatic NSCLC who harbor a BRAF V600E mutation," said Melissa Johnson, M.D., Director of Lung Cancer Research at Sarah Cannon Research Institute and PHAROS investigator.
"These findings, which highlight the potential impact of encorafenib and binimetinib for newly diagnosed metastatic NSCLC patients with BRAF V600E, offer renewed optimism for their prognosis and treatment goals."
Lung cancer is the number one cause of cancer-related deaths around the world. NSCLC accounts for approximately 80-85% of lung cancers, with BRAF V600E mutations occurring in about 2% of patients with NSCLC.3 Prior to the development of targeted treatments, patients with BRAF V600E-mutant metastatic NSCLC had poor outcomes with standard chemotherapy.
At the time of this analysis, the safety profile of BRAFTOVI + MEKTOVI was consistent with previous findings. The most common (≥30%) treatment-related adverse events were nausea (52%), diarrhea (44%), fatigue (33%), and vomiting (30%).
"These long-term survival results reinforce Pfizer's unwavering commitment to improving outcomes in lung cancer," said Jeff Legos, Chief Oncology Officer, Pfizer. "The findings provide hope for treatment-naïve BRAF V600E mNSCLC patients and their families and underscore the importance of advancing therapies that can provide a sustained impact for patients.”